expressgraft-c9t1 skin tissue
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2017 (NCT02657876)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- expressgraft-c9t1 skin tissue
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04134143 | Phase 1 | Nov 30, 2019 | Stratatech Corporation |
| NCT02657876 | Phase 1 | Oct 1, 2017 | Mallinckrodt, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mallinckrodt | For profit | 1 | 1 | 1 | 2017 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2017 |
| Stratatech Corporation | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1